brexpiprazole

Contraindicated in:

Hypersensitivity.

Use Cautiously in:

History of seizures or concurrent use of medications that may ↓ seizure threshold;
Pre-existing cardiovascular disease, dehydration, hypotension, concurrent antihypertensives, diuretics, electrolyte imbalance (↑ risk of orthostatic hypotension, correct deficits before treatment);
Pre-existing low WBC (may ↑ risk of leukopenia/neutropenia);
History of diabetes, metabolic syndrome, or dyslipidemia (may exacerbate);
May ↑ risk of suicide attempt/ideation especially during early treatment or dose adjustment; risk may be greater in children or adolescents;
Patients at risk for falls;
Poor CYP2D6 metabolizers (↓ dose);
OB: Use during 3rd trimester may result in extrapyramidal/withdrawal symptoms in infant; use during pregnancy only if potential maternal benefit justifies potential fetal risk;
Lactation: Safety not established during breastfeeding;
Pedi: Safety and effectiveness not established in children <18 yr (major depressive disorder) or <13 yr (schizophrenia);
Geri:
Appears on Beers list. ↑ risk of stroke, cognitive decline, and mortality in older adults with dementia. Avoid use in older adults, except for schizophrenia, adjunctive treatment of major depressive disorder, or agitation associated with dementia due to Alzheimer disease (not indicated for dementia-related psychosis without agitation)
.

Adv. Reactions/Side Effects ⬆ ⬇

CV: cerebrovascular adverse reactions (↑ in older adults with dementia-related psychoses), orthostatic hypotension/syncope

EENT: blurred vision

Endo: hyperglycemia/diabetes

GI: abdominal pain, constipation, diarrhea, dry mouth, dysphagia, excess salivation, flatulence

Hemat: agranulocytosis, leukopenia, neutropenia

Metab: weight gain, ↑appetite, dyslipidemia

Neuro: akathisia, abnormal dreams, cognitive impairment, dizziness, drowsiness, dystonia, extrapyramidal symptoms, headache, NEUROLEPTIC MALIGNANT SYNDROME, restlessness, sedation, SEIZURES, SUICIDAL THOUGHTS/BEHAVIORS, tardive dyskinesia, tremor, urges (eating, gambling, sexual, shopping)

Misc: body temperature dysregulation, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS)

Interactions ⬆ ⬇

Drug-drug:

Strong CYP3A4 inhibitors, including clarithromycin, itraconazole or ketoconazole, may ↑ levels and risk of toxicity; ↓ dose.
Strong CYP2D6 inhibitors, including fluoxetine, paroxetine, or quinidine, may ↑ levels and risk of toxicity; ↓ dose.
Combined use of strong or moderate CYP3A4 inhibitors with strong or moderate CYP2D6 inhibitors in addition to brexpiprazole, including the following combinations: itraconazole + quinidine, fluconazole + paroxetine, itraconazole + duloxetine or fluconazole + duloxetine—may ↑ levels and risk of toxicity; ↓ dose.
Strong CYP3A4 inducers, including rifampin, may ↓ levels and effectiveness; ↑ dose.
Antihypertensives or diuretics may ↑ the risk of hypotension.
Medications that may seizure threshold may ↑ the risk of seizures.

Drug-Natural Products:

St. John's wort may ↓ levels and effectiveness; ↑ dose.

Availability ⬆ ⬇

(Generic available)

Tablets: 0.25 mg; 0.5 mg; 1 mg; 2 mg; 3 mg; 4 mg

Route/Dosage ⬆ ⬇

Schizophrenia

PO (Adults ): 1 mg once daily on Days 1–4; then ↑ to 2 mg once daily on Days 5–7; then ↑ to 4 mg once daily on Day 8 (not to exceed 4 mg once daily). Known CYP2D6 poor metabolizers: Use 50% of the usual dose. Concurrent use of strong CYP2D6 inhibitors (schizophrenia only) or CYP3A4 inhibitors: Use 50% of the usual dose; Concurrent use of strong/moderate CYP2D6 inhibitors AND strong/moderate CYP3A4 inhibitors: Use 25% of the usual dose; Known CYP2D6 poor metabolizer taking concurrent strong/moderate CYP3A4 inhibitors: Use 25% of the usual dose; Concurrent use of strong CYP3A4 inducers: Double usual dose over 1–2 wk; titrate by clinical response.
PO (Children 13–17 yr): 0.5 mg once daily on Days 1–4; then ↑ to 1 mg once daily on Days 5–7; then ↑ to 2 mg once daily on Day 8. May ↑ dose by 1 mg/day on weekly basis (not to exceed 4 mg once daily). Known CYP2D6 poor metabolizers: Use 50% of the usual dose. Concurrent use of strong CYP2D6 inhibitors (schizophrenia only) or CYP3A4 inhibitors: Use 50% of the usual dose; Concurrent use of strong/moderate CYP2D6 inhibitors AND strong/moderate CYP3A4 inhibitors: Use 25% of the usual dose; Known CYP2D6 poor metabolizer taking concurrent strong/moderate CYP3A4 inhibitors: Use 25% of the usual dose; Concurrent use of strong CYP3A4 inducers: Double usual dose over 1–2 wk; titrate by clinical response.

Renal Impairment

PO (Adults and Children 13–17 yr): CCr <60 mL/min: Maximum daily dose should not exceed 3 mg.

Hepatic Impairment

(Adults and Children 13–17 yr): Moderate to severe hepatic impairment: Maximum daily dose should not exceed 3 mg.

Major Depressive Disorder

PO (Adults ): 0.5 or 1 mg once daily initially; may be ↑ to 2 mg once daily (not to exceed 3 mg once daily); Known CYP2D6 poor metabolizers: Use 50% of the usual dose. Concurrent use of strong CYP2D6 inhibitors (schizophrenia only) or CYP3A4 inhibitors: Use 50% of the usual dose; Concurrent use of strong/moderate CYP2D6 inhibitors AND strong/moderate CYP3A4 inhibitors: Use 25% of the usual dose; Known CYP2D6 poor metabolizer taking concurrent strong/moderate CYP3A4 inhibitors: Use 25% of the usual dose; Concurrent use of strong CYP3A4 inducers: Double usual dose over 1–2 wk; titrate by clinical response.

Renal Impairment

PO (Adults ): CCr <60 mL/min: Maximum daily dose should not exceed 2 mg.

Hepatic Impairment

PO (Adults ): Moderate to severe hepatic impairment: Maximum daily dose should not exceed 2 mg.

Agitation Associated With Dementia Due to Alzheimer Disease

PO (Adults ): 0.5 mg once daily on Days 1–7; then ↑ to 1 mg once daily on Days 8–14; then ↑ to 2 mg once daily on Day 15. May ↑ to 3 mg once daily after ≥14 days based on clinical response and tolerability. Known CYP2D6 poor metabolizers: Use 50% of the usual dose. Concurrent use of strong CYP2D6 inhibitors (schizophrenia only) or CYP3A4 inhibitors: Use 50% of the usual dose; Concurrent use of strong/moderate CYP2D6 inhibitors AND strong/moderate CYP3A4 inhibitors: Use 25% of the usual dose; Known CYP2D6 poor metabolizer taking concurrent strong/moderate CYP3A4 inhibitors: Use 25% of the usual dose; Concurrent use of strong CYP3A4 inducers: Double usual dose over 1–2 wk; titrate by clinical response.

Renal Impairment

PO (Adults ): CCr <60 mL/min: Maximum daily dose should not exceed 2 mg.

Hepatic Impairment

PO (Adults ): Moderate to severe hepatic impairment: Maximum daily dose should not exceed 2 mg.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Psychotropic activity may be due to partial agonist activity at dopamine D₂ and serotonin 5-HT_1A receptors and antagonist activity at the 5-HT_2A receptor.

Therapeutic effects:

Decreased manifestations of schizophrenia, including excitable, paranoic, or withdrawn behavior.
Improvement in symptoms of depression with increased sense of well-being.
Decreased agitation associated with dementia due to Alzheimer disease.

Classifications ⬆ ⬇

Therapeutic Classification: antipsychotics, antidepressants

Pharmacologic Classification: serotonin-dopamine activity modulators (SDAM)

Pharmacokinetics ⬆ ⬇

Absorption: Well absorbed (95%) following oral administration.

Distribution: Well distributed to tissues.

Protein Binding: >99%.

Metabolism/Excretion: Primarily metabolized by the liver via the CYP3A4 and CYP2D6 isoenzymes; the CYP2D6 enzyme system exhibits genetic polymorphism (∼7% of population may be poor metabolizers and may have significantly ↑ brexpiprazole concentrations and an ↑ risk of adverse effects). 25% excreted in urine (<1% unchanged); 46% in feces (14% unchanged).

Half-Life: 91 hr.

Time/Action Profile ⬆ ⬇

(improvement in symptoms)

ROUTE	ONSET	PEAK	DURATION
PO (schizophrenia)	within 1–2 wk	4–6 wk	unknown
PO (depression)	within 1 wk	5 wk	unknown

Patient/Family Teaching ⬆ ⬇

Advise patient to take medication as directed and not to skip doses or double up on missed doses. Take missed doses as soon as remembered unless almost time for the next dose. Do not stop taking brexpiprazole without consulting health care provider. Advise patient to read Medication Guide before starting and with each Rx refill in case of changes.
Inform patient of possibility of extrapyramidal symptoms and tardive dyskinesia. Instruct patient to report these symptoms immediately.
Advise patient to make position changes slowly to minimize orthostatic hypotension. Protect from falls.
Medication may cause drowsiness and light-headedness. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
Advise patient, family, and caregivers to look for suicidality, especially during early therapy or dose changes. Notify health care provider immediately if thoughts about suicide or dying, attempts to commit suicide, new or worse depression or anxiety, agitation or restlessness, panic attacks, insomnia, new or worse irritability, aggressiveness, acting on dangerous impulses, mania, or other changes in mood or behavior occur.
Advise patient and family to notify health care provider if signs and symptoms of high blood sugar (feel very thirsty, urinating more than usual, feel very hungry, feel weak or tired, nausea, confusion, breath smells fruity) occur.
Inform patient that brexipiprazole may cause weight gain. Advise patient to monitor weight periodically. Notify health care provider of significant weight gain.
Instruct patient to notify health care provider of all Rx or OTC medications, vitamins, or herbal products being taken and to consult health care provider before taking any new medications. Caution patient to avoid taking alcohol or other CNS depressants concurrently with this medication.
Advise patient that extremes in temperature should be avoided because this drug impairs body temperature regulation.
Advise patient to notify health care provider if new or ↑ eating/binge eating or gambling, sexual, shopping, or other impulse control disorders occur.
Advise patient to notify health care provider of medication regimen prior to treatment or surgery.
Rep: May cause fetal harm. Advise women of reproductive potential to notify health care provider if pregnancy is planned or suspected and to avoid breastfeeding during therapy. May cause extrapyramidal and/or withdrawal symptoms (agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder) in neonates whose mothers were exposed to antipsychotic drugs during 3rd trimester of pregnancy. Symptoms vary in severity. Some neonates recover within hours or days without specific treatment; others require prolonged hospitalization. Monitor neonates for extrapyramidal and/or withdrawal symptoms and manage symptoms appropriately. Encourage pregnant patients to enroll in registry by contacting National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/.
Emphasize the importance of routine follow-up exams and continued participation in psychotherapy as indicated.

Pronunciation ⬆ ⬇

Code ⬆

NDC Code

12658- ZAKLADY FARMACEUTYCZNE POLPHARMA S A
- 12658-0501-
  - 12658-0501-1- 1 kg in 1 DRUM (12658-0501-1)

27241- Ajanta Pharma USA Inc.
- 27241-204- Brexpiprazole
  - 27241-204-30- 30 TABLET in 1 BOTTLE (27241-204-30)

27241- Ajanta Pharma USA Inc.
- 27241-205- Brexpiprazole
  - 27241-205-30- 30 TABLET in 1 BOTTLE (27241-205-30)

27241- Ajanta Pharma USA Inc.
- 27241-206- Brexpiprazole
  - 27241-206-30- 30 TABLET in 1 BOTTLE (27241-206-30)

27241- Ajanta Pharma USA Inc.
- 27241-207- Brexpiprazole
  - 27241-207-30- 30 TABLET in 1 BOTTLE (27241-207-30)

27241- Ajanta Pharma USA Inc.
- 27241-208- Brexpiprazole
  - 27241-208-30- 30 TABLET in 1 BOTTLE (27241-208-30)

27241- Ajanta Pharma USA Inc.
- 27241-209- Brexpiprazole
  - 27241-209-30- 30 TABLET in 1 BOTTLE (27241-209-30)

46602- OTSUKA PHARMACEUTICAL CO. LTD.
- 46602-0001-
  - 46602-0001-1- 10 kg in 1 DRUM (46602-0001-1)

46602- OTSUKA PHARMACEUTICAL CO., LTD.
- 46602-0035-
  - 46602-0035-5- 170000 TABLET in 1 DRUM (46602-0035-5)

46602- OTSUKA PHARMACEUTICAL CO., LTD.
- 46602-0036-
  46602-0036-5- 170000 TABLET in 1 DRUM (46602-0036-5)

46602- OTSUKA PHARMACEUTICAL CO., LTD.
- 46602-0037-
  46602-0037-5- 170000 TABLET in 1 DRUM (46602-0037-5)

46602- OTSUKA PHARMACEUTICAL CO., LTD.
- 46602-0038-
  46602-0038-5- 170000 TABLET in 1 DRUM (46602-0038-5)

46602- OTSUKA PHARMACEUTICAL CO., LTD.
- 46602-0039-
  46602-0039-5- 170000 TABLET in 1 DRUM (46602-0039-5)

46602- OTSUKA PHARMACEUTICAL CO., LTD.
- 46602-0040-
  46602-0040-5- 170000 TABLET in 1 DRUM (46602-0040-5)

53747- Unichem Laboratories Limited, India
- 53747-084-
  53747-084-00- 1 BAG in 1 DRUM (53747-084-00) / 50 kg in 1 BAG

59148- Otsuka America Pharmaceutical, Inc.
- 59148-035- Rexulti
  59148-035-13- 1 BOTTLE in 1 CARTON (59148-035-13) / 30 TABLET in 1 BOTTLE

59148- Otsuka America Pharmaceutical, Inc.
- 59148-036- Rexulti
  - 59148-036-07- 1 BLISTER PACK in 1 CARTON (59148-036-07) / 7 TABLET in 1 BLISTER PACK

59148- Otsuka America Pharmaceutical, Inc.
- 59148-036- Rexulti
  - 59148-036-13- 1 BOTTLE in 1 CARTON (59148-036-13) / 30 TABLET in 1 BOTTLE

59148- Otsuka America Pharmaceutical, Inc.
- 59148-037- Rexulti
  - 59148-037-07- 1 BLISTER PACK in 1 CARTON (59148-037-07) / 7 TABLET in 1 BLISTER PACK

59148- Otsuka America Pharmaceutical, Inc.
- 59148-037- Rexulti
  - 59148-037-13- 1 BOTTLE in 1 CARTON (59148-037-13) / 30 TABLET in 1 BOTTLE

59148- Otsuka America Pharmaceutical, Inc.
- 59148-038- Rexulti
  - 59148-038-07- 1 BLISTER PACK in 1 CARTON (59148-038-07) / 7 TABLET in 1 BLISTER PACK

59148- Otsuka America Pharmaceutical, Inc.
- 59148-038- Rexulti
  - 59148-038-13- 1 BOTTLE in 1 CARTON (59148-038-13) / 30 TABLET in 1 BOTTLE

59148- Otsuka America Pharmaceutical, Inc.
- 59148-039- Rexulti
  - 59148-039-07- 1 BLISTER PACK in 1 CARTON (59148-039-07) / 7 TABLET in 1 BLISTER PACK

59148- Otsuka America Pharmaceutical, Inc.
- 59148-039- Rexulti
  - 59148-039-13- 1 BOTTLE in 1 CARTON (59148-039-13) / 30 TABLET in 1 BOTTLE

59148- Otsuka America Pharmaceutical, Inc.
- 59148-040- Rexulti
  - 59148-040-07- 1 BLISTER PACK in 1 CARTON (59148-040-07) / 7 TABLET in 1 BLISTER PACK

59148- Otsuka America Pharmaceutical, Inc.
- 59148-040- Rexulti
  - 59148-040-13- 1 BOTTLE in 1 CARTON (59148-040-13) / 30 TABLET in 1 BOTTLE

59148- Otsuka America Pharmaceutical, Inc.
- 59148-042- Rexulti
  - 59148-042-07- 1 KIT in 1 CARTON (59148-042-07) * 4 TABLET in 1 BLISTER PACK * 3 TABLET in 1 BLISTER PACK

59148- Otsuka America Pharmaceutical, Inc.
- 59148-044- Rexulti
  - 59148-044-14- 1 KIT in 1 CARTON (59148-044-14) * 7 TABLET in 1 BLISTER PACK * 7 TABLET in 1 BLISTER PACK

59651- Aurobindo Pharma Limited
- 59651-328-
  - 59651-328-37- 50 kg in 1 DRUM (59651-328-37)

60219- Amneal Pharmaceuticals NY LLC
- 60219-1649- brexpiprazole
  60219-1649-3- 1 BOTTLE, PLASTIC in 1 CARTON (60219-1649-3) / 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC

60219- Amneal Pharmaceuticals NY LLC
- 60219-1650- brexpiprazole
  - 60219-1650-3- 1 BOTTLE, PLASTIC in 1 CARTON (60219-1650-3) / 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC

60219- Amneal Pharmaceuticals NY LLC
- 60219-1651- brexpiprazole
  - 60219-1651-3- 1 BOTTLE, PLASTIC in 1 CARTON (60219-1651-3) / 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC

60219- Amneal Pharmaceuticals NY LLC
- 60219-1652- brexpiprazole
  - 60219-1652-3- 1 BOTTLE, PLASTIC in 1 CARTON (60219-1652-3) / 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC

60219- Amneal Pharmaceuticals NY LLC
- 60219-1653- brexpiprazole
  - 60219-1653-3- 1 BOTTLE, PLASTIC in 1 CARTON (60219-1653-3) / 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC

60219- Amneal Pharmaceuticals NY LLC
- 60219-1654- brexpiprazole
  - 60219-1654-3- 1 BOTTLE, PLASTIC in 1 CARTON (60219-1654-3) / 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC

60274- Societal CDMO Gainesville, LLC
- 60274-935-
  - 60274-935-05- 170000 TABLET in 1 DRUM (60274-935-05)

60274- Societal CDMO Gainesville, LLC
- 60274-936-
  60274-936-05- 170000 TABLET in 1 DRUM (60274-936-05)

60274- Societal CDMO Gainesville, LLC
- 60274-937-
  60274-937-05- 170000 TABLET in 1 DRUM (60274-937-05)

60274- Societal CDMO Gainesville, LLC
- 60274-938-
  60274-938-05- 170000 TABLET in 1 DRUM (60274-938-05)

60274- Societal CDMO Gainesville, LLC
- 60274-939-
  60274-939-05- 170000 TABLET in 1 DRUM (60274-939-05)

60274- Societal CDMO Gainesville, LLC
- 60274-940-
  60274-940-05- 170000 TABLET in 1 DRUM (60274-940-05)

64220- Zhejiang Huahai Pharmaceutical Co., Ltd.
- 64220-205-
  64220-205-05- 10 kg in 1 DRUM (64220-205-05)

64220- Zhejiang Huahai Pharmaceutical Co., Ltd.
- 64220-205-
  64220-205-06- 15 kg in 1 DRUM (64220-205-06)

64220- Zhejiang Huahai Pharmaceutical Co., Ltd.
- 64220-205-
  64220-205-07- 20 kg in 1 DRUM (64220-205-07)

65129- ScinoPharm Taiwan Ltd.
- 65129-1401-
  65129-1401-0- 3082 g in 1 BAG (65129-1401-0)

65372- Jubilant Pharmova Limited
- 65372-1201-
  65372-1201-2- 20 kg in 1 DRUM (65372-1201-2)

69037- Honour Lab Limited
- 69037-0035-
  69037-0035-1- 25 kg in 1 DRUM (69037-0035-1)

69766- MSN Life Sciences Private Limited
- 69766-041-
  69766-041-02- 25 kg in 1 DRUM (69766-041-02)

69766- MSN Life Sciences Private Limited
- 69766-041-
  69766-041-05- 5 kg in 1 DRUM (69766-041-05)

75929- Pharma Packaging Solutions, LLC dba Tjoapack LLC
- 75929-273- Rexulti
  75929-273-03- 1 BOTTLE in 1 CARTON (75929-273-03) / 30 TABLET in 1 BOTTLE

76055- Sionc Pharmaceutical Private Limited
- 76055-0040-
  - 76055-0040-1- 60 kg in 1 DRUM (76055-0040-1)

section name header

Indications ⬇

Contraind./Precautions ⬆ ⬇

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Availability ⬆ ⬇

Route/Dosage ⬆ ⬇

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Classifications ⬆ ⬇

Pharmacokinetics ⬆ ⬇

Time/Action Profile ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Pronunciation ⬆ ⬇

Code ⬆